Targeting cardiolipin modification in a genetic disorder
Barth syndrome, an X-linked disorder that primarily affects males, is characterized by weak skeletal muscles, cardiomyopathy and low neutrophils (the white blood cells that fight bacteria), among other medical concerns. The symptoms can be treated, but no disease-specific therapies have been approved. This rare and serious lipid metabolism disorder is caused by pathogenic variants in the gene TAFAZZIN.

TAFAZZIN encodes for an enzyme involved in the final remodeling step of cardiolipin, a key phospholipid localized to the mitochondrial inner membrane. TAFAZZIN deficiency results in abnormal mitochondrial cardiolipin quantity and composition and subsequent mitochondrial dysfunction. Whereas researchers have known the primary biochemical defect in Barth syndrome for several decades, two important questions have remained unanswered: What molecular pathways are impacted by TAFAZZIN deficiency and contribute to resultant mitochondrial dysfunction? And why does deficiency of an enzyme that affects a molecule present in every cell in the body affect such a specific set of tissues? Answering these questions is key to developing treatments for Barth syndrome.
Combined proteomic, metabolomic and functional studies in a CRISPR-edited TAFAZZIN knockout HEK293 cell model recently have offered insight into these questions. Among the molecular abnormalities that researchers at the Johns Hopkins School of Medicine identified in this cellular model were defects in the expression, assembly and function of complex I of the mitochondrial respiratory chain. The researchers also found increased expression of presenilin-associated rhomboidlike protein, a protease localized to the inner mitochondrial membrane, and abnormal cleavage of its downstream target, phosphoglycerate mutase 5. Thus, TAFAZZIN deficiency affects mitochondrial respiratory chain function and quality control.
The researchers found that both elamipretide, a molecule that binds to cardiolipin, and bromoenol lactone, which inhibits nascent cardiolipin deacylation, partially remediate these mitochondrial defects. Determining if these pathways are differentially impacted in spared versus affected tissues may help researchers understand what causes the pleiotropic effects of TAFAZZIN deficiency and suggest therapeutic approaches.
In addition to demonstrating the effects of cardiolipin targeting in cellular models of TAFAZZIN deficiency in the lab, this approach has shown clinical promise. In a recent study published in the journal Genetics in Medicine, clinical researchers at the Johns Hopkins School of Medicine described results of a placebo-controlled, crossover clinical trial to investigate the role of elamipretide in 12 patients affected by Barth syndrome. The study participants showed improvement in multiple clinical parameters, including muscle strength, exercise tolerance and cardiac stroke volume, after 48 weeks of treatment.
Together, these studies show the translational potential of cellular disease modeling and pathway targeting in lipid metabolism disorders.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

A biological camera: How AI is transforming retinal imaging
AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.

AI-designed biomarker improves malaria diagnostics
Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.

Matrix metalloproteinase inhibitor reduces cancer invasion
Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted cancer research.

Antibiotic sensor directly binds drug in resistant bacteria
Researchers at Drexel University uncover how the vancomycin-resistant bacterial sensor binds to the antibiotic, offering insights to guide inhibitor design that restores antibiotic effectiveness against hospital-acquired infections.